Keywords: آنتاگونیست muscarinic طولانی مدت; Bronchodilator agents; Electrocardiography; GFF MDI; Pulmonary disease; Chronic obstructive; Holter monitoring; QT prolongation; AE; adverse event; AV; atrioventricular; BID; twice daily; BMI; body mass index; bpm; beats per minute; CI; confidence interva
مقالات ISI آنتاگونیست muscarinic طولانی مدت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آنتاگونیست muscarinic طولانی مدت; COPD; Budesonide; Formoterol fumarate dihydrate; Glycopyrronium; Co-suspension delivery technology; Pharmacokinetic; AE; adverse event; AUC0-â; area under the plasma concentration-time curve from time 0 to infinity; AUC0-12; area under the plasma
Keywords: آنتاگونیست muscarinic طولانی مدت; Inhaled drugs; Drug delivery; Pressurized metered-dose inhalers; Drug formulation; COPD; chronic obstructive pulmonary disease; DPI; dry powder inhaler; FDC; fixed-dose combination; HFA; hydrofluoroalkane; GOLD; Global Initiative for Chronic Obstructive L
Keywords: آنتاگونیست muscarinic طولانی مدت; The trial was registered under NCT02433834 at; http://www.clinicaltrials.gov; Asthma; Co-suspension delivery technology; Glycopyrronium; Inhaled corticosteroid use; Metered dose inhaler; ACQ-5; Asthma Control Questionnaire-5; AE; adverse event; AUC0-3;
Keywords: آنتاگونیست muscarinic طولانی مدت; DPI; dry powder inhaler; eNPV; expected net present value; LAMA; long-acting muscarinic antagonist; LABA; long-acting β-agonist; NPV; net present value; pMDI; pressurized metered-dose inhaler; COPD; chronic obstructive pulmonary disease; Estimated net pr
Keywords: آنتاگونیست muscarinic طولانی مدت; 6MWT; 6-min walk test; GOLD; Global Initiative for Chronic Obstructive Lung Disease; IC; inspiratory capacity; IPF; idiopathic pulmonary fibrosis; LABA; long-acting β-agonist; LAMA; long-acting muscarinic antagonist; mMRC; modified Medical Research Counc
Keywords: آنتاگونیست muscarinic طولانی مدت; Corticosteroids; bronchodilator; cytokine; chemokine; IgE; kinase; p38 mitogen-activated protein kinase; bronchial thermoplasty; corticosteroid resistance; macrolide; ACOS; Asthma-chronic obstructive pulmonary disease overlap syndrome; COPD; Chronic obs
POINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% â¤Â FEV1 < 50% Predicted) COPD? Yes
Keywords: آنتاگونیست muscarinic طولانی مدت; GOLD; Global Initiative for Chronic Obstructive Lung Disease; ICS; inhaled corticosteroid; LABA; long-acting β2-agonist; LAMA; long-acting muscarinic antagonist;
Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA
Keywords: آنتاگونیست muscarinic طولانی مدت; Combination therapy; COPD; Inhaled corticosteroids; Long-acting bronchodilators; LAMA/LABA; Fixed-dose dual bronchodilators; CDS; Chronic Disease Score; CI; confidence interval; COPD; chronic obstructive pulmonary disease; ER; emergency room; FDC; fixed-d
Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease
Keywords: آنتاگونیست muscarinic طولانی مدت; Co-suspension delivery technology; Formoterol fumarate dihydrate; Glycopyrronium; Metered dose inhaler; Spacer; Valved holding chamber; AE; adverse event; ANOVA; analysis of variance; AUC0-12; area under the curve from 0 to 12â¯h; BMI; body mass index;
Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β2-agonists for adults with asthma
Keywords: آنتاگونیست muscarinic طولانی مدت; Tiotropium; Long-acting muscarinic antagonist; Long-acting β2-agonist; Inhaled corticosteroids; Asthma; ACRN; Asthma Clinical Research Network; AE; adverse event; B16-Arg/Arg; arginine single nucleotide polymorphism at amino acid 16 in the β2-adrenergic
COPD Guidelines: A Review of the 2018 GOLD Report
Keywords: آنتاگونیست muscarinic طولانی مدت; AECOPD; acute exacerbation of COPD; CAT; COPD Assessment Test; COPD; chronic obstructive pulmonary disease; GOLD; Global Initiative for Chronic Obstructive Lung Disease; FEV1; forced expiratory volume in 1 second; FVC; forced vital capacity; ICS; inhaled
Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects
Keywords: آنتاگونیست muscarinic طولانی مدت; GFF MDI; Chronic obstructive pulmonary disease; Co-suspension delivery technology; LAMA/LABA; Pharmacokinetics; AE; adverse event; AUC0-12; area under the curve from 0 to 12â¯h; AUC0-t; area under the curve from 0 to time of the last measurable plasm
Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent
Keywords: آنتاگونیست muscarinic طولانی مدت; Chronic obstructive pulmonary disease; Co-suspension delivery technology; ICS/LAMA/LABA; Western; Japanese; Triple fixed-dose combination; AE; adverse event; AUC0-12; area under the plasma concentration-time curve from 0 to 12â¯h; AUC0-â; area un
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies
Keywords: آنتاگونیست muscarinic طولانی مدت; Bronchodilator; COPD; Long-acting muscarinic antagonist; Revefenacin; Rapid onset; Nebulized; Once-daily; Inhalation; Anti-muscarinic;
Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease
Keywords: آنتاگونیست muscarinic طولانی مدت; COPD; Long-acting muscarinic antagonist; Long-acting β-agonist; Safety; Maintenance bronchodilator; AE; adverse event; COPD; chronic obstructive pulmonary disease; GOLD; Global initiative for chronic Obstructive Lung Disease; LABA; long-acting β2-agonis
Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease
Keywords: آنتاگونیست muscarinic طولانی مدت; AE; adverse event; AUC0-3; area under the curve from 0 to 3Â h; COPD; chronic obstructive pulmonary disease; FEV1; forced expiratory volume in 1Â s; FVC; forced vital capacity; GOLD; Global initiative for chronic Obstructive Lung Disease; ICH-E1; Intern
The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study
Keywords: آنتاگونیست muscarinic طولانی مدت; Asthma; Chronic obstructive pulmonary disease; Inhaled corticosteroids; Long-acting muscarinic antagonist; Umeclidinium; AE; adverse event; AESI; AEs of special interest; ANCOVA; analysis of covariance; CI; confidence interval; COPD; chronic obstructive p
Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β2-adrenoceptor agonist (MABA) molecule
Keywords: آنتاگونیست muscarinic طولانی مدت; COPD; Bronchodilator; Long-acting β2-adrenoceptor agonist; Long-acting muscarinic antagonist; ACh; acetylcholine; ANOVA; analysis of variance; β; beta-adrenoceptor; cAMP; cyclic adenosine monophosphate; CHO; Chinese hamster ovary; CI; confidence interva
Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD
Keywords: آنتاگونیست muscarinic طولانی مدت; bronchodilators; chronic bronchitis; combination therapy; emphysema; metered dose inhalers; CAT; COPD Assessment Test; FF; formoterol fumarate; GFF; glycopyrrolate/formoterol fumarate; GOLD; Global Initiative for Chronic Obstructive Lung Disease; GP; glyc
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD
Keywords: آنتاگونیست muscarinic طولانی مدت; β2-agonist; bronchodilator; chronic bronchitis; emphysema; muscarinic antagonists; AE; adverse event; ATS; American Thoracic Society; CAT; COPD Assessment Test; DPI; dry powder inhaler; FDC; fixed-dose combination; FEV1 AUC0-12; FEV1 area under the curv
Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3)
Keywords: آنتاگونیست muscarinic طولانی مدت; Bronchodilator; Chronic obstructive pulmonary disease; Safety; Glycopyrrolate; Long-acting muscarinic antagonist; Indacaterol;
Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: Pooled analysis of SHINE and ARISE
Keywords: آنتاگونیست muscarinic طولانی مدت; AE; adverse event; CCV; cerebro-cardiovascular; CI; confidence interval; DPI; dry powder inhaler; ECG; electrocardiography; FEV1; forced expiratory volume in one second; FVC; forced vital capacity; GOLD; Global Initiative for Chronic Obstructive Lung Dise
Acute Exacerbations of COPD Are Associated With Increased Expression of Heparan Sulfate and Chondroitin Sulfate in BAL
Keywords: آنتاگونیست muscarinic طولانی مدت; airway inflammation; airway obstruction; bronchoalveolar lavage; COPD; AECOPD; acute exacerbation of COPD; CV; coefficient of variability; ECM; extracellular matrix; ELISA; enzyme-linked immunosorbent assay; GAG; glycosaminoglycan; ICS; inhaled corticoste
Effect of tiotropium on COPD exacerbations: A systematic review
Keywords: آنتاگونیست muscarinic طولانی مدت; Anticholinergic; Antimuscarinic; COPD; Long-acting muscarinic antagonist;
Roflumilast added to triple therapy in patients with severe COPD: AÂ real life study
Keywords: آنتاگونیست muscarinic طولانی مدت; COPD exacerbations; Phosphodiesterase-4 inhibitors; Combination therapy; Side effects; AECOPD; acute exacerbation of COPD; ICS; inhaled corticosteroids; LABA; long-acting β-agonist; LAMA; long-acting muscarinic antagonist; PDE-4; phosphodiesterase-4;
Tiotropium + olodaterol shows clinically meaningful improvements in quality of life
Keywords: آنتاگونیست muscarinic طولانی مدت; COPD; Quality of life; Long-acting bronchodilator; Tiotropium; Olodaterol; AE; adverse event; AUC0-3; area under the curve from 0 to 3Â h; COPD; chronic obstructive pulmonary disease; FEV1; forced expiratory volume in 1Â s; GOLD; Global initiative for c
Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies
Keywords: آنتاگونیست muscarinic طولانی مدت; Long-acting muscarinic antagonist; Inhaled corticosteroid; Long-acting beta2 agonist; Bronchodilation; AE; adverse event; ASE; all subjects enrolled; CAT; COPD Assessment Test; CI; confidence interval; COPD; chronic obstructive pulmonary disease; FEV1; fo
Characterization of V0162, a new long-acting antagonist at human M3 muscarinic acetylcholine receptors
Keywords: آنتاگونیست muscarinic طولانی مدت; ACh; acetylcholine; COPD; chronic obstructive pulmonary disease; EFS; electrical field stimulation; hM3R; human muscarinic M3 acetylcholine receptor; KHS; Krebs-Henseleit solution; LABA; long-acting beta adrenergic agonist; LAMA; long-acting muscarinic
A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma
Keywords: آنتاگونیست muscarinic طولانی مدت; Asthma; Fixed-dose combination; Muscarinic antagonist; Inhaled corticosteroid; Trough FEV1; Ae; amount of dose excreted unchanged in urine; AE; adverse event; ALT; alanine aminotransferase; AUC; area under the curve; BID; twice daily; bpm; beats per minut
Economic Burden of COPD in the Presence of Comorbidities
Keywords: آنتاگونیست muscarinic طولانی مدت; CKD; chronic kidney disease; CVD; cardiovascular disease; GLM; generalized linear model; ICS; inhaled corticosteroid; LABA; long-acting β2-adrenergic agonist; LAMA; long-acting muscarinic antagonist; MI; myocardial infarction;
A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD
Keywords: آنتاگونیست muscarinic طولانی مدت; AE; adverse event; FSC; fluticasone propionate/salmeterol; ICS; inhaled corticosteroid; LABA; long-acting Ã2-agonist; LAMA; long-acting muscarinic antagonist; MCID; minimal clinically important difference; NNTB; number needed to treat for benefit; SAE; s
Efficacy and safety of umeclidinium/vilanterol 62.5/25Â mcg and tiotropium 18Â mcg in chronic obstructive pulmonary disease: Results of a 24-week, randomized, controlled trial
Keywords: آنتاگونیست muscarinic طولانی مدت; Long-acting bronchodilator; Umeclidinium; Vilanterol; AE; adverse event; CI; confidence interval; COPD; chronic obstructive pulmonary disease; DPI; Dry powder inhaler; FEV1; forced expiratory volume in one second; FP; fluticasone propionate; FVC; forced v
Efficacy and Safety of a Fixed-Dose Combination of Indacaterol and Glycopyrronium for the Treatment of COPD
Keywords: آنتاگونیست muscarinic طولانی مدت; AE; adverse event; LABA; long-acting β2-agonist; LAMA; long-acting muscarinic antagonist; MCID; minimal clinical important difference; NNTB; number needed to treat for benefit; QVA149; fixed-dose combination of indacaterol and glycopyrronium; SAE; seriou
Effects of Moderate Hepatic Impairment on the Pharmacokinetic Properties and Tolerability of Umeclidinium and Vilanterol in Inhalational Umeclidinium Monotherapy and Umeclidinium/Vilanterol Combination Therapy: An Open-Label, Nonrandomized Study
Keywords: آنتاگونیست muscarinic طولانی مدت; chronic obstructive pulmonary disease; GSK573719; long-acting β2-agonist; long-acting muscarinic antagonist; umeclidinium; vilanterol;
Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile
Keywords: آنتاگونیست muscarinic طولانی مدت; Aclidinium; Inhaled COPD treatment; Long-acting muscarinic antagonist; Low plasma exposure; Renal safety; Urinary safety
Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients
Keywords: آنتاگونیست muscarinic طولانی مدت; NVA237; Long-acting muscarinic antagonist; COPD; 24-h bronchodilation; Efficacy
Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients
Keywords: آنتاگونیست muscarinic طولانی مدت; NVA237; Long-acting muscarinic antagonist; COPD; Tiotropium; Efficacy; Safety